December 2009 Reports finding from a study showing that access to antiretroviral therapies, HAART in particular, can improve the health of HIV-infected patients who have a history of injection drug use.
April 2013 Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.
February 2013 Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.
October 2014 Nano-antiretroviral therapy (nano-ART) turns macrophages—one of the very cell types that HIV uses to replicate and spread through the body—into carriers for anti-HIV medications. The approach has the potential to make treatment for HIV easier and more effective.
March 2011 Describes a study revealing that HIV-infected prisoners in Texas often experience an interruption in treatment following their release and that assistance in filling out paperwork can reduce these interruptions.
April 2014 Intensified screening for HIV among injection drug users receiving opioid agonist therapy could prevent more than twice as many new infections as current screening practice. A recent study based on mathematical modeling found that screening every 6 months instead of annually, and adding viral RNA testing to the currently used HIV antibody testing, could improve both effectiveness and cost-effectiveness.
September 2017 Inhibiting mTOR, a regulatory protein complex, can prevent reactivation of latent HIV. Medications to inhibit mTOR might help people with HIV achieve and maintain undetectable HIV viral loads.
October 2007 Highlights data on the risky sexual behaviors of patients at a sexually transmitted disease clinic who had a substance abuse disorder as compared to those without a substance abuse disorder.